At the time of writing, Apellis Pharmaceuticals Inc [APLS] stock is trading at $19.21, up 5.49%. An important factor to consider is whether the stock is rising or falling in short-term value. The APLS shares have gain 9.83% over the last week, with a monthly amount drifted -12.16%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock has seen the most recent analyst activity on April 29, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $44. Previously, Goldman downgraded its rating to Neutral on December 17, 2024, and kept the price target unchanged to $36. On November 21, 2024, Morgan Stanley initiated with a Equal-Weight rating and assigned a price target of $31 on the stock. RBC Capital Mkts started tracking the stock assigning a Sector Perform rating and suggested a price target of $25 on October 25, 2024. William Blair initiated its recommendation with a Outperform. In a note dated May 31, 2024, Piper Sandler initiated an Neutral rating and provided a target price of $46 on this stock.
For the past year, the stock price of Apellis Pharmaceuticals Inc fluctuated between $16.98 and $49.06. Currently, Wall Street analysts expect the stock to reach $57 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $19.21 at the most recent close of the market. An investor can expect a potential return of 196.72% based on the average APLS price forecast.
Analyzing the APLS fundamentals
According to Apellis Pharmaceuticals Inc [NASDAQ:APLS], the company’s sales were 781.37M for trailing twelve months, which represents an 45.19% jump. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.21%, Pretax Profit Margin comes in at -0.25%, and Net Profit Margin reading is -0.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.79 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.24 points at the first support level, and at 17.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.69, and for the 2nd resistance point, it is at 20.18.
Ratios To Look Out For
It is important to note that Apellis Pharmaceuticals Inc [NASDAQ:APLS] has a current ratio of 4.25. On the other hand, the Quick Ratio is 3.81, and the Cash Ratio is 2.22. Considering the valuation of this stock, the price to sales ratio is 3.09, the price to book ratio is 10.46.
Transactions by insiders
Recent insider trading involved Chopas James George, VP/Chief Accounting Officer, that happened on Mar 17 ’25 when 183.0 shares were sold. Officer, Chopas James George completed a deal on Mar 17 ’25 to buy 183.0 shares. Meanwhile, General Counsel Watson David O. sold 5569.0 shares on Mar 05 ’25.
